Details of the Drug Combination

General Information of Drug Combination (ID: DCWTF3Z)

• Drug Combination Name: Vitamin B3 + Idarubicin
• Indication: Glioblastoma?; Status: Investigative [1]
• Component Drugs:
  Vitamin B3 (DMQVRZH): Small molecular drug
  Idarubicin (DMM0XGL): Small molecular drug
• High-throughput Screening Result:
  Testing Cell Line: T98G
  Zero Interaction Potency (ZIP) Score: 4.39
  Bliss Independence Score: 4.39
  Loewe Additivity Score: 8.1
  LHighest Single Agent (HSA) Score: 8.17

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Vitamin B3

Disease Entry	ICD 11	Status	REF
Chronic renal failure	GB61.Z	Approved	[2]
Hypercholesterolaemia	5C80.0	Approved	[3]
Hyperlipidemia	5C80.Z	Approved	[4]
Hyperlipidemia, familial combined, LPL related	N.A.	Approved	[5]
Hypertriglyceridemia	5C80.1	Approved	[6]
Lipid metabolism disorder	5C52.Z	Approved	[7]
Primary hypercholesterolemia	5C80.00	Approved	[8]
Psoriasis	EA90	Approved	[9]
Vitamin deficiency	5B55-5B71	Approved	[10]

Vitamin B3 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Nicotinic acid receptor (HCAR2)	TTWNV8U	HCAR2_HUMAN	Agonist	[7]
Diacylglycerol O-acyltransferase 2 (DGAT2)	TTRHEQ4	DGAT2_HUMAN	Inhibitor	[7]

Vitamin B3 Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cyclic ADP-ribose hydrolase 1 (CD38)	DEGF70S	CD38_HUMAN	Metabolism	[14]

Vitamin B3 Interacts with 32 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Long-chain fatty acid transport protein 2 (SLC27A2)	OT7JEG5F	S27A2_HUMAN	Increases Expression	[15]
Phospholipid-transporting ATPase ABCA1 (ABCA1)	OT94G6BQ	ABCA1_HUMAN	Increases Expression	[16]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Increases Expression	[17]
C-reactive protein (CRP)	OT0RFT8F	CRP_HUMAN	Decreases Expression	[18]
Apolipoprotein B-100 (APOB)	OTH0UOCZ	APOB_HUMAN	Decreases Expression	[17]
Intercellular adhesion molecule 1 (ICAM1)	OTTOIX77	ICAM1_HUMAN	Decreases Expression	[19]
ATP synthase subunit beta, mitochondrial (ATP5F1B)	OTLFZUQK	ATPB_HUMAN	Decreases Expression	[20]
Apolipoprotein(a) (LPA)	OTRZLU9F	APOA_HUMAN	Decreases Expression	[21]
C-C motif chemokine 2 (CCL2)	OTAD2HEL	CCL2_HUMAN	Decreases Expression	[22]
Platelet endothelial cell adhesion molecule (PECAM1)	OTXOM4D9	PECA1_HUMAN	Decreases Expression	[19]
Platelet glycoprotein 4 (CD36)	OT5CZWKY	CD36_HUMAN	Increases Expression	[15]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2)	OTIN6G20	CPT2_HUMAN	Decreases Expression	[23]
Proteinase-activated receptor 1 (F2R)	OT4WVWBO	PAR1_HUMAN	Increases Expression	[13]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Increases Expression	[16]
Leptin (LEP)	OT5Q7ODW	LEP_HUMAN	Increases Expression	[24]
Hydroxycarboxylic acid receptor 3 (HCAR3)	OTJBHLX0	HCAR3_HUMAN	Increases Expression	[15]
Fatty acid synthase (FASN)	OTFII9KG	FAS_HUMAN	Decreases Expression	[23]
CCAAT/enhancer-binding protein alpha (CEBPA)	OTOM9OE4	CEBPA_HUMAN	Increases Expression	[23]
CCAAT/enhancer-binding protein delta (CEBPD)	OTNBIPMY	CEBPD_HUMAN	Increases Expression	[23]
5'-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2)	OTU1KZPV	AAPK2_HUMAN	Increases Activity	[25]
Hormone-sensitive lipase (LIPE)	OTMMVJ8A	LIPS_HUMAN	Decreases Expression	[23]
Peroxisome proliferator-activated receptor alpha (PPARA)	OTK095PP	PPARA_HUMAN	Increases Expression	[26]
Platelet-activating factor acetylhydrolase (PLA2G7)	OT6H6AMO	PAFA_HUMAN	Decreases Expression	[18]
Oxysterols receptor LXR-alpha (NR1H3)	OT54YZ9I	NR1H3_HUMAN	Increases Expression	[16]
Adiponectin (ADIPOQ)	OTNX23LE	ADIPO_HUMAN	Increases Expression	[23]
Long-chain fatty acid transport protein 4 (SLC27A4)	OTWT4HAF	S27A4_HUMAN	Increases Expression	[15]
NAD-dependent protein deacetylase sirtuin-2 (SIRT2)	OT5Q6SVK	SIR2_HUMAN	Increases Expression	[27]
Scavenger receptor class B member 1 (SCARB1)	OTAE1UA1	SCRB1_HUMAN	Increases Expression	[16]
Diacylglycerol O-acyltransferase 2 (DGAT2)	OTE5PDD0	DGAT2_HUMAN	Decreases Activity	[28]
Resistin (RETN)	OTW5Z1NH	RETN_HUMAN	Decreases Expression	[29]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A)	OTHCDQ22	PRGC1_HUMAN	Increases Expression	[30]
NAD-dependent protein lipoamidase sirtuin-4, mitochondrial (SIRT4)	OT5S0J23	SIR4_HUMAN	Increases Expression	[27]

Indication(s) of Idarubicin

Disease Entry	ICD 11	Status	REF
Acute myelogenous leukaemia	2A41	Approved	[11]
Acute myeloid leukaemia	2A60	Approved	[12]
Adult acute monocytic leukemia	N.A.	Approved	[11]
Childhood acute megakaryoblastic leukemia	N.A.	Approved	[11]
Leukemia	N.A.	Approved	[11]

Idarubicin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Modulator	[32]

Idarubicin Interacts with 3 DTP Molecule(s)

DTP Name	DTP ID	UniProt ID	Mode of Action	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[33]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[34]
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[34]

Idarubicin Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Metabolism	[35]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[35]

Idarubicin Interacts with 9 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Estrogen receptor (ESR1)	OTKLU61J	ESR1_HUMAN	Decreases Activity	[31]
Heme oxygenase 1 (HMOX1)	OTC1W6UX	HMOX1_HUMAN	Increases Expression	[36]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Increases Activity	[31]
Natriuretic peptides B (NPPB)	OTSN2IPY	ANFB_HUMAN	Increases Expression	[37]
Peroxisome proliferator-activated receptor gamma (PPARG)	OTHMARHO	PPARG_HUMAN	Decreases Activity	[31]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Activity	[38]
Peroxisome proliferator-activated receptor delta (PPARD)	OTI4WTOP	PPARD_HUMAN	Decreases Activity	[31]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Decreases Activity	[39]
Bile acid receptor (NR1H4)	OTWZLPTB	NR1H4_HUMAN	Decreases Activity	[31]

References

• [1] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [2] Nicotinamide for photoprotection and skin cancer chemoprevention: A review of efficacy and safety. Exp Dermatol. 2019 Feb;28 Suppl 1:15-22.
• [3] Vitamin B3 impairs reverse cholesterol transport in Apolipoprotein E-deficient mice. Clin Investig Arterioscler. 2019 Nov-Dec;31(6):251-260.
• [4] Vitamin B3. 2024 Feb 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 JanC.
• [5] A standard database for drug repositioning. Sci Data. 2017 Mar 14;4:170029.
• [6] Niacin: chemical forms, bioavailability, and health effects. Nutr Rev. 2012 Jun;70(6):357-66.
• [7] Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
• [8] Extended-release niacin (nicotinic acid)/laropiprant. Drugs. 2009 Aug 20;69(12):1665-79.
• [9] Cosmeceutical Aptitudes of Niacinamide: A Review. Recent Adv Antiinfect Drug Discov. 2021;16(3):196-208.
• [10] Hydrosoluble vitamins. Handb Clin Neurol. 2014;120:891-914.
• [11] Idarubicin FDA Label
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
• [13] The in vitro effects of niacin on platelet biomarkers in human volunteers. Thromb Haemost. 2010 Aug;104(2):311-7. doi: 10.1160/TH10-01-0015. Epub 2010 Jun 10.
• [14] ADP-ribosyl cyclase and CD38 catalyze the synthesis of a calcium-mobilizing metabolite from NADP. J Biol Chem. 1995 Dec 22;270(51):30327-33.
• [15] Structure-dependent effects of pyridine derivatives on mechanisms of intestinal fatty acid uptake: regulation of nicotinic acid receptor and fatty acid transporter expression. J Nutr Biochem. 2014 Jul;25(7):750-7. doi: 10.1016/j.jnutbio.2014.03.002. Epub 2014 Mar 22.
• [16] Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol. 2004 Feb 1;67(3):411-9. doi: 10.1016/j.bcp.2003.09.014.
• [17] Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001 Nov;21(11):1783-9. doi: 10.1161/hq1001.096624.
• [18] Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006 Sep 15;98(6):743-5. doi: 10.1016/j.amjcard.2006.04.011. Epub 2006 Jul 26.
• [19] Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic Clin Pharmacol Toxicol. 2009 Mar;104(3):206-10. doi: 10.1111/j.1742-7843.2008.00364.x. Epub 2009 Jan 21.
• [20] Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells: implications for raising HDL. J Lipid Res. 2008 Jun;49(6):1195-201. doi: 10.1194/jlr.M700426-JLR200. Epub 2008 Mar 3.
• [21] Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes. Diabetes Obes Metab. 2002 Jul;4(4):255-61. doi: 10.1046/j.1463-1326.2002.00205.x.
• [22] Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis. 2009 Jan;202(1):68-75. doi: 10.1016/j.atherosclerosis.2008.04.044. Epub 2008 May 9.
• [23] Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis. 2009 Jul;205(1):207-13. doi: 10.1016/j.atherosclerosis.2008.11.026. Epub 2008 Dec 3.
• [24] Extended-release niacin raises adiponectin and leptin. Atherosclerosis. 2007 Aug;193(2):361-5. doi: 10.1016/j.atherosclerosis.2006.06.028. Epub 2006 Aug 2.
• [25] Reduced plasma FFA availability increases net triacylglycerol degradation, but not GPAT or HSL activity, in human skeletal muscle. Am J Physiol Endocrinol Metab. 2004 Jul;287(1):E120-7. doi: 10.1152/ajpendo.00542.2003. Epub 2004 Jan 28.
• [26] Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells. J Nutr Biochem. 2009 Apr;20(4):261-8. doi: 10.1016/j.jnutbio.2008.02.010. Epub 2008 Jul 7.
• [27] Effects of niacin restriction on sirtuin and PARP responses to photodamage in human skin. PLoS One. 2012;7(7):e42276. doi: 10.1371/journal.pone.0042276. Epub 2012 Jul 31.
• [28] Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004 Oct;45(10):1835-45. doi: 10.1194/jlr.M300403-JLR200. Epub 2004 Jul 16.
• [29] Adipokines and treatment with niacin. Metabolism. 2006 Oct;55(10):1283-5. doi: 10.1016/j.metabol.2006.07.002.
• [30] A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
• [31] Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
• [32] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [33] Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
• [34] Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
• [35] In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
• [36] A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
• [37] The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
• [38] The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
• [39] Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.